Hazel Lote, PhD, Institute of Cancer Research, Sutton, UK, discusses findings from a sub-study of the Phase II PLATFORM trial (NCT02678182) analyzing microRNAs as potential biomarkers of resistance to trastuzumab in patients with esophago-gastric cancer (GEC). Previous studies have determined high miR-148a-3p levels to negatively impact progression-free survival (PFS) and overall survival (OS). Whilst miR-148a-3p levels were not linked to PFS and OS in the sub-analysis, it was linked to 3-month
progression-free rates post- trastuzumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.